Close
Nordic 9Nordic 9

CR-CP Life Science Fund (investor - Venture Capital)

Hong Kong
See something wrong or missing? Let us know
Offices:Hong Kong

CR-CP Life Science Fund is a joint venture set up by China Resources Group and Charoen Pokphand Group investing in life science companies that develop drugs and cell therapies, medical devices, and smart healthcare technology.

Average round investment:33.02M USD
Average number per year:1.0
Distribution: 2021 (1)2020 (1)
Portfolio companies: Belgium Novadip BiosciencesUnited Kingdom ReViral
Mostly invests in: Belgium Belgium (1) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to CR-CP Life Science Fund

Name Criteria
United States Bicycle Day Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Honeywell Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Manufacturing, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Evotec AG
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Rick Klausner
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Japan Kyoritsu Holdings
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Digitalis Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium InvestSud
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Northpond Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium VIB
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Belgium V-Bio Ventures
82%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Belgium
  • Average number of deals per year: 1.2
  • Active last 12 months: Yes
Top